331 related articles for article (PubMed ID: 18070865)
1. Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.
Thone J
J Neuropsychiatry Clin Neurosci; 2007; 19(4):481-2. PubMed ID: 18070865
[No Abstract] [Full Text] [Related]
2. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
[TBL] [Abstract][Full Text] [Related]
4. Aripirazole-olanzapine combination for treatment of schizophrenia.
Duggal HS
Can J Psychiatry; 2004 Feb; 49(2):151. PubMed ID: 15065751
[No Abstract] [Full Text] [Related]
5. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?
DeQuardo JR
J Clin Psychiatry; 2004 Jan; 65(1):132-3. PubMed ID: 14976671
[No Abstract] [Full Text] [Related]
6. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
Chen CH; Huang MC; Lu ML
J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
[No Abstract] [Full Text] [Related]
7. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Kane JM; Barnes TR; Correll CU; Sachs G; Buckley P; Eudicone J; McQuade R; Tran QV; Pikalov A; Assunção-Talbott S
J Psychopharmacol; 2010 Jul; 24(7):1019-29. PubMed ID: 20008446
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD
Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
[TBL] [Abstract][Full Text] [Related]
9. Torticollis after low-dose aripiprazole administration in a Thai schizophrenia patient.
Ittasakul P; Srivastava S; Hiranyatheb T; Ketter TA
Asian J Psychiatr; 2012 Dec; 5(4):365-6. PubMed ID: 23174451
[No Abstract] [Full Text] [Related]
10. Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia.
Guirguis-Blake J
Am Fam Physician; 2010 Jun; 81(11):1335-6. PubMed ID: 20521753
[No Abstract] [Full Text] [Related]
11. Intramuscular aripiprazole in the acute management of psychomotor agitation.
De Filippis S; Cuomo I; Lionetto L; Janiri D; Simmaco M; Caloro M; De Persis S; Piazzi G; Simonetti A; Telesforo CL; Sciarretta A; Caccia F; Gentile G; Kotzalidis GD; Girardi P
Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients.
Crossman AM; Lindenmayer JP
J Clin Psychiatry; 2006 Jul; 67(7):1158-9. PubMed ID: 16889465
[No Abstract] [Full Text] [Related]
13. Intramuscular aripiprazole in the control of agitation.
Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
[TBL] [Abstract][Full Text] [Related]
14. Pathological gambling and the treatment of psychosis with aripiprazole: case reports.
Smith N; Kitchenham N; Bowden-Jones H
Br J Psychiatry; 2011 Aug; 199(2):158-9. PubMed ID: 21804151
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents.
Prescrire Int; 2009 Dec; 18(104):251. PubMed ID: 20025091
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Tran-Johnson TK; Sack DA; Marcus RN; Auby P; McQuade RD; Oren DA
J Clin Psychiatry; 2007 Jan; 68(1):111-9. PubMed ID: 17284138
[TBL] [Abstract][Full Text] [Related]
17. Switching antipsychotic medications: not enough, too often, or just right?
Weiden PJ
Am J Psychiatry; 2011 Sep; 168(9):882-4. PubMed ID: 21890800
[No Abstract] [Full Text] [Related]
18. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
[TBL] [Abstract][Full Text] [Related]
19. Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy.
Shajahan P; Macrae A; Bashir M; Taylor M
J Psychopharmacol; 2008 Sep; 22(7):778-83. PubMed ID: 18308790
[TBL] [Abstract][Full Text] [Related]
20. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.
Citrome L
J Clin Psychiatry; 2007 Dec; 68(12):1876-85. PubMed ID: 18162018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
